Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | OGG1 | O15527 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2967940 | 0.86 | TRIM24 (0.55) | LMNAMAPK1SMN1; SMN2KDM4ETRIM24 | |
| SCHEMBL5658758 | 0.84 | WDR5 (0.46) | WDR5KMT2AKCNH2OGG1LMNA | |
| SCHEMBL5661304 | 0.84 | WDR5 (0.46) | WDR5KMT2AKCNH2OGG1LMNA | |
| SCHEMBL19513578 | 0.82 | HTR1D (0.57) | KMT2ADRD2DRD4 | |
| SCHEMBL19513368 | 0.82 | HTR1D (0.57) | KMT2ADRD2DRD4 | |
| SCHEMBL24767008 | 0.82 | WDR5 (0.49) | WDR5KMT2AKCNH2OGG1LMNA | |
| SCHEMBL13251265 | 0.81 | HTT (0.54) | WDR5KMT2AKCNH2LMNAMAPK1 | |
| SCHEMBL19501387 | 0.81 | KMT2A (0.47) | WDR5KMT2AKCNH2OGG1DRD2 | |
| SCHEMBL19501397 | 0.81 | KMT2A (0.47) | WDR5KMT2AKCNH2OGG1DRD2 | |
| SCHEMBL11463788 | 0.81 | MAOA (0.65) | WDR5KMT2AKCNH2OGG1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229649-B2 | Methods for treating cryptosporidiosis using triazolopyridazines | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190343837-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2019-11-14 | — | — | US | disclosed |
| US-10363254-B2 | Methods for treating cryptosporidiosis using triazolopyridazines | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2018-03-08 | — | — | US | disclosed |
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2018-03-08 | — | — | US | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-8853237-B2 | Naphthyridinone analogs as mGluR5 positive allosteric modulators | VANDERBILT UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| US-7498458-B2 | Process for the preparation of prostaglandins and analogues thereof | RESOLUTION CHEMICALS LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-7498458-B2 | Process for the preparation of prostaglandins and analogues thereof | RESOLUTION CHEMICALS LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080312308-A1 | SUBSTITUTED ACETIC ACID DERIVATIVES | WYETH (US) | 2008-12-18 | — | — | US | disclosed |
| US-7411083-B2 | Substituted acetic acid derivatives | WYETH (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070254920-A1 | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use | AERIE PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-7268239-B2 | Process for the preparation of prostaglandins and analogues thereof | RESOLUTION CHEMICALS LIMITED (GB) | 2007-09-11 | — | — | US | disclosed |
| US-7268239-B2 | Process for the preparation of prostaglandins and analogues thereof | RESOLUTION CHEMICALS LIMITED (GB) | 2007-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | WDR5 2127/4885KMT2A 3692/4885KCNH2 4203/4885 |
| US-11229649-B2 | Methods for treating cryptosporidiosis using triazolopyridazines | CLPP, SI, SAMHD1 | WDR5 1629/4885KMT2A 3111/4885KCNH2 643/4885 |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | DHPS, FDPS, DPYD | WDR5 2221/4885KMT2A 3719/4885KCNH2 2364/4885 |
| US-20190343837-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | CLPP, SI, SAMHD1 | WDR5 1629/4885KMT2A 3111/4885KCNH2 643/4885 |
| US-20070254920-A1 | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use | HCAR1, HCAR2, PAICS | WDR5 4263/4885KMT2A 3127/4885KCNH2 1918/4885 |
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | CLPP, SI, SAMHD1 | WDR5 1629/4885KMT2A 3111/4885KCNH2 643/4885 |
| US-10363254-B2 | Methods for treating cryptosporidiosis using triazolopyridazines | CLPP, SI, SAMHD1 | WDR5 1629/4885KMT2A 3111/4885KCNH2 643/4885 |
| US-20080312308-A1 | SUBSTITUTED ACETIC ACID DERIVATIVES | AADAC, ACACA, AANAT | WDR5 4528/4885KMT2A 1541/4885KCNH2 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.